VRDN
Viridian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.92
−0.17%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.3x
Market Cap
$2.60B
MomentumView details →
1D Return
−0.17%
YTD Return
−26.69%
RSI (14)
52.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.3x
Market Cap
$2.60B
RSI (14)
52.7
MomentumView details →
1D Return
−0.17%
YTD Return
−26.69%
SummaryUpdated Jun 1, 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biotechnology company founded in 2006 and headquartered in Waltham, Massachusetts. Originally established as Miragen Therapeutics, the company underwent a strategic transformation and rebranded to Viridian Therapeutics in January 2021. The company has evolved from its initial focus on microRNA-based therapeutics to become a specialized developer of antibody treatments targeting serious autoimmune and rare diseases, with particular emphasis on thyroid eye disease.
Similar companies
Latest newsMore news →
Viridian Therapeutics reported its Q2 2026 financial results, with total revenues of $284,000 and a net loss of $127.1 million.30d agoViridian Therapeutics received early FDA approval for Lumvoa, a treatment for thyroid eye disease.66d agoThe U.S. FDA approved Lumvoa (veligrotug-vvze) developed by Viridian Therapeutics for the treatment of thyroid eye disease.70d ago